Effectiveness of Behavioral Activation Treatment for Schizophrenia

Effectiveness of Non Face-to-face Behavioral Activation Treatment for Negative Symptoms of Schizophrenia

NCT05764148•Inha University Hospital

Summary

The purpose of this study is to implement a behavior activation remote program for negative symptoms of schizophrenia and to verify whether the behavior activation remote program for negative symptoms of schizophrenia has effects on negative symptoms, cognitive function, and social function of schizophrenia.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who have received a primary diagnosis of schizophrenia
•Patients who are at least 18 years old and under 65 years old
•Patients who show a score of 3 or higher on at least two negative symptom items in the Positive and Negative Syndrome Scale (PANSS)
•The subject selection period is until December 31, 2021, from the IRB approval date.

Exclusion Criteria

•Patients with a history of organic brain syndrome, epilepsy, or traumatic brain injury
•Patients with comorbidities such as intellectual disability, current alcohol or other substance dependence
•Patients who show a score of 5 or higher on at least two positive symptom items in the Positive and Negative Syndrome Scale (PANSS)
•Patients who have received a diagnosis of major depressive disorder according to the DSM-V criteria by a specialist in psychiatry
•Patients who have received psychological services including components of behavioral activation therapy
•Patients who are at risk of self-harm or harm to others.

Locations (1)

Inha university hospital

Incheon, Jung-Gu, South Korea

Key Dates

Start Date

March 1, 2021

Primary Completion Date

September 1, 2023

Completion Date

December 31, 2023

Last Updated

March 10, 2023

Enrollment

ESTIMATED participants

Conditions

Schizophrenia, LatentNegative Symptoms in SchizophreniaBehavioral ActivationRemote Medical Service

Interventions

behavioral activation

BEHAVIORAL

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

NCT06763081

Behavioral ActivationMajor Depressive Disorder+4 more

View study

RECRUITINGNA

40 Hz Visual Stimulation as an Intervention in Schizophrenia

NCT06907420

Negative Symptoms in SchizophreniaSchizophrenia Disorders+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effectiveness of Behavioral Activation Treatment for Schizophrenia

Inclusion Criteria

Exclusion Criteria

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

40 Hz Visual Stimulation as an Intervention in Schizophrenia

ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia

Online HD-tDCS Over the Left DLPFC During a Working Memory Task for Treating Negative Symptoms of Schizophrenia

NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia

A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia